Last updated: April 24, 2026
CN102834096 is a Chinese patent publication that covers a specific pharmaceutical invention in China. A complete, claim-by-claim scope map and a legally actionable landscape requires the full published specification (including claim set, dependent claim relationships, and key embodiments) and a normalized bibliographic record (assignee, priority, filing date, status, and cited references). That information is not present in the input provided here, so a complete and accurate analysis cannot be produced.
What does CN102834096 claim (independent and dependent scope)?
No claim text (independent claim wording, dependent claim dependencies, or claim numbering) was provided. Without the published claim set, scope cannot be reconstructed without risk of material error.
What is the claim architecture and coverage boundaries?
No description of:
- active ingredient(s) or chemical structures,
- formulation types (salt, polymorph, hydrate),
- dosing regimens,
- therapeutic indications,
- process claims (manufacturing route) vs product claims,
- Markush groups vs single species coverage
was provided. Those elements determine:
- the legal “breadth” of genus vs species,
- exclusion risk against nearby compounds,
- and the enforceable product definition for infringement and clearance.
What is the usable “freedom to operate” risk profile in China?
A credible FTO risk profile requires, at minimum:
- CN102834096 exact claim scope,
- all forward and backward citations from the publication,
- co-pending related families in China (continuations/divisionals, if any),
- and the status of relevant comparator patents (grants, rejections, invalidations, term adjustments).
No bibliographic or citation data was provided.
How does CN102834096 sit in the broader China drug patent landscape?
Landscape placement depends on:
- therapeutic class and molecular identity,
- priority timeline vs competing filings at CNIPA,
- family members across CN and WO/EP/US,
- and whether CN102834096 is a composition-of-matter, method-of-treatment, or process patent.
No such identifiers were provided.
Key Takeaways
- A complete and accurate scope and claims analysis for CN102834096 cannot be produced without the published claim set and full specification content.
- Landscape mapping for CN102834096 cannot be performed without bibliographic record fields and citation/relationship data needed to identify relevant Chinese family members and adjacent patents.
FAQs
-
Can a reliable claim scope be derived from the publication number alone?
No. The publication number does not contain the claim text, embodiments, or dependency structure required for legal scope mapping.
-
What inputs are essential to perform an investment-grade CN drug patent landscape?
Full claim text, specification embodiments, bibliographic family data, and citation/relationship links to identify enforceable and competing rights.
-
Does CN drug landscape analysis focus on granted claims only?
It must incorporate publication scope and grant outcomes; but the claim text and status are required to determine enforceable coverage.
-
How do process claims versus composition claims change landscape risk?
They shift infringement theory and clearance strategy, but the classification must be taken from the actual CN102834096 claim set.
-
What is the difference between “genus” and “species” coverage in patent scope?
Genus claims can cover multiple compounds under shared structural/functional language; species claims cover specific structures. Determining which applies requires the exact claim language.
Sources
No sources were provided in the prompt to cite.
